Free Trial

Xenon Pharmaceuticals (XENE) News Today

Xenon Pharmaceuticals logo
$29.75 -0.74 (-2.43%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$30.50 +0.75 (+2.52%)
As of 05/23/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

XENE Latest News

Xenon Pharmaceuticals Inc. stock logo
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Acquired by Two Sigma Advisers LP
Two Sigma Advisers LP lifted its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 9.1% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 298,700 shares of the biopharmaceutical company's stock after purchas
Xenon Pharmaceuticals Inc. stock logo
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Rating Lowered by StockNews.com
StockNews.com downgraded shares of Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Wednesday.
Xenon Pharmaceuticals Inc. stock logo
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of "Buy" by Brokerages
Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) have received a consensus rating of "Buy" from the twelve ratings firms that are covering the firm, Marketbeat.com reports. Twelve research analysts have rated the stock with a buy recommendation. The average twelve-month price o
Xenon Pharmaceuticals Inc. stock logo
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Vestal Point Capital LP
Vestal Point Capital LP lessened its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 1.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 810,000 shares of the
Xenon Pharmaceuticals Inc. stock logo
D. E. Shaw & Co. Inc. Sells 117,919 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
D. E. Shaw & Co. Inc. lowered its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 57.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 86,973 shares of the biopharmaceutical company's sto
Xenon Pharmaceuticals Inc. stock logo
Ensign Peak Advisors Inc Sells 136,970 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Ensign Peak Advisors Inc cut its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 84.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 26,094 shares of the biopharmaceutical company's stock after selli
Xenon Pharmaceuticals Inc. stock logo
Leerink Partnrs Issues Optimistic Forecast for XENE Earnings
Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Analysts at Leerink Partnrs upped their Q2 2025 earnings per share (EPS) estimates for shares of Xenon Pharmaceuticals in a research note issued on Tuesday, May 13th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical
Xenon Pharmaceuticals Inc. stock logo
Sphera Funds Management LTD. Acquires Shares of 52,097 Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Sphera Funds Management LTD. acquired a new stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 52,097 shares of the biopharmaceutical company's
Xenon Pharmaceuticals Inc. stock logo
Polar Capital Holdings Plc Increases Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Polar Capital Holdings Plc increased its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 10.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,697,657 shares o
Xenon Pharmaceuticals Inc. stock logo
HC Wainwright Issues Positive Outlook for XENE Earnings
Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Research analysts at HC Wainwright upped their Q2 2025 EPS estimates for Xenon Pharmaceuticals in a research note issued to investors on Tuesday, May 13th. HC Wainwright analyst D. Tsao now anticipates that the biopharmaceutical company wil
Q2 EPS Estimate for Xenon Pharmaceuticals Lifted by Analyst
Xenon Pharmaceuticals Inc. stock logo
Traders Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)
Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) saw unusually large options trading activity on Wednesday. Traders bought 4,063 put options on the stock. This is an increase of approximately 2,362% compared to the average volume of 165 put options.
Leerink Partnrs Issues Positive Outlook for XENE Earnings
Xenon Pharmaceuticals Inc. stock logo
MPM Bioimpact LLC Increases Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
MPM Bioimpact LLC raised its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 18.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 197,212 shares of the biopharmaceutical company's stock after
Wedbush Equities Analysts Cut Earnings Estimates for XENE
Xenon Pharmaceuticals Inc. stock logo
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Down on Analyst Downgrade
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Down Following Analyst Downgrade
Xenon Pharmaceuticals Inc. stock logo
Xenon Pharmaceuticals (NASDAQ:XENE) Given "Buy" Rating at HC Wainwright
HC Wainwright reaffirmed a "buy" rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a research report on Tuesday.
Xenon Pharmaceuticals Inc. stock logo
Xenon Pharmaceuticals' (XENE) Buy Rating Reiterated at Chardan Capital
Chardan Capital restated a "buy" rating and set a $55.00 price target on shares of Xenon Pharmaceuticals in a research report on Tuesday.
Xenon Pharmaceuticals Inc. stock logo
Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Lowered to $55.00 at Needham & Company LLC
Needham & Company LLC cut their price target on Xenon Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating on the stock in a report on Tuesday.
Xenon Pharmaceuticals Inc. stock logo
Orbimed Advisors LLC Has $37.16 Million Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Orbimed Advisors LLC raised its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 4.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 947,877 shares of the biopharmaceutical
Xenon Pharmaceuticals Inc. stock logo
Janus Henderson Group PLC Boosts Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Janus Henderson Group PLC increased its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 12.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,866,755 shares of the biopharmaceut
Xenon Pharmaceuticals Inc. stock logo
Xenon Pharmaceuticals (NASDAQ:XENE) Announces Earnings Results
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) announced its earnings results on Monday. The biopharmaceutical company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($0.94) by $0.11.
Xenon Pharmaceuticals Inc. stock logo
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Granahan Investment Management LLC
Granahan Investment Management LLC trimmed its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 9.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 182,333 shares of the biopharmaceuti
Xenon Pharmaceuticals Inc. stock logo
Balyasny Asset Management L.P. Buys 100,382 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Balyasny Asset Management L.P. raised its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 119.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 184,580 shares of the bi
Xenon Pharmaceuticals Inc. stock logo
Tudor Investment Corp ET AL Reduces Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Tudor Investment Corp ET AL decreased its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 76.4% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 8,671 shares of the biopharmaceutical company's stock after selling 28,016 shares during
Xenon Pharmaceuticals Inc. stock logo
Dimensional Fund Advisors LP Reduces Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Dimensional Fund Advisors LP lessened its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 13.3% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 259,970 shares of the biopharmaceutical company's stock aft
Xenon Pharmaceuticals Inc. stock logo
Driehaus Capital Management LLC Has $177.21 Million Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Driehaus Capital Management LLC cut its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 1.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,520,595 shares of the biopharma
Xenon Pharmaceuticals Inc. stock logo
Chardan Capital Initiates Coverage on Xenon Pharmaceuticals (NASDAQ:XENE)
Chardan Capital assumed coverage on shares of Xenon Pharmaceuticals in a research report on Wednesday. They set a "buy" rating and a $55.00 price objective for the company.
Xenon Pharmaceuticals Inc. stock logo
169,132 Shares in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Acquired by Deep Track Capital LP
Deep Track Capital LP purchased a new stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 169,132 shares of the biopharmaceutical company's stock, v
Xenon Pharmaceuticals Inc. stock logo
Raymond James Financial Inc. Makes New Investment in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Raymond James Financial Inc. acquired a new stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 20,331 shares of the biopharmaceutical company's stock, value
Xenon Pharmaceuticals Inc. stock logo
Braidwell LP Boosts Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Braidwell LP boosted its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 7.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,913,964 shares of the biopharmaceutical co
Xenon Pharmaceuticals Inc. stock logo
Xenon Pharmaceuticals' (XENE) Outperform Rating Reiterated at William Blair
William Blair reaffirmed an "outperform" rating on shares of Xenon Pharmaceuticals in a research report on Monday.
Get Xenon Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter.

XENE Media Mentions By Week

XENE Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

XENE
News Sentiment

1.38

0.77

Average
Medical
News Sentiment

XENE News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

XENE Articles
This Week

7

5

XENE Articles
Average Week

Get Xenon Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:XENE) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners